Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 5/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975665 | 0.86 | CHUK (0.41) | CHUKCYP1A2CYP3A4TGFBR1AR | |
| SCHEMBL13835385 | 0.83 | LRRK2 (0.53) | CHUKLRRK2IMPDH2IMPDH1AR | |
| SCHEMBL4209183 | 0.73 | CYP11B1 (0.49) | CHUKLRRK2CYP11B1CYP11B2GSK3B | |
| SCHEMBL25395833 | 0.72 | MPL (0.50) | CHUKCYP1A2CYP3A4CYP11B1CYP11B2 | |
| SCHEMBL25394131 | 0.72 | L3MBTL1 (0.48) | CHUKCYP1A2CYP11B1CYP11B2MAP4K1 | |
| SCHEMBL3827956 | 0.69 | LRRK2 (0.53) | CHUKLRRK2IMPDH2IMPDH1DYRK1A | |
| SCHEMBL21274452 | 0.69 | LRRK2 (0.53) | CHUKLRRK2IMPDH2IMPDH1DYRK1A | |
| SCHEMBL13834754 | 0.69 | LRRK2 (0.53) | CHUKLRRK2IMPDH2IMPDH1DYRK1A | |
| SCHEMBL16417049 | 0.68 | CYP1A2 (0.49) | CYP1A2CYP3A4TGFBR1MAP4K1ALOX5AP | |
| SCHEMBL20910479 | 0.67 | ALOX5AP (0.46) | CHUKCYP11B1CYP11B2ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2709997-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| CN-103582637-B | Tyrosine kinase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-12 | — | — | CN | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729078-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| EP-2709997-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| CN-103582637-A | Tyrosine Kinase Inhibitors | HOFFMANN LA ROCHE | 2014-02-12 | — | — | CN | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2012-11-22 | — | — | US | disclosed |
| WO-2012156334-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295885-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | CHUK 12/4885LRRK2 952/4885IMPDH2 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.